Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274224 | 0.87 | CSNK2A1 (0.67) | CSNK2A1HTR2AHTR2CGPR84HTR6 | |
| SCHEMBL6198753 | 0.80 | GPR84 (0.67) | CSNK2A1HTR2AGPR84CYP2A6 | |
| SCHEMBL29352833 | 0.80 | GPR84 (0.67) | CSNK2A1HTR2AHTR2CGPR84HTR6 | |
| SCHEMBL29354243 | 0.80 | CSNK2A1 (0.77) | CSNK2A1HTR2AHTR2CIMPDH2GPR84 | |
| SCHEMBL18708142 | 0.80 | CSNK2A1 (0.57) | CSNK2A1HTR2AHTR2CGPR84MEN1 | |
| SCHEMBL1242939 | 0.80 | GPR84 (0.67) | CSNK2A1HTR2AHTR2CGPR84HTR6 | |
| SCHEMBL15074715 | 0.80 | HTR2A (0.59) | CSNK2A1HTR2AHTR2CGPR84MEN1 | |
| SCHEMBL6029334 | 0.80 | CSNK2A1 (0.77) | CSNK2A1HTR2AHTR2CIMPDH2GPR84 | |
| SCHEMBL4185239 | 0.79 | HTR2A (0.53) | HTR2AHTR2CIMPDH2GPR84HTR6 | |
| SCHEMBL14964102 | 0.78 | CSNK2A1 (0.54) | CSNK2A1HTR2AHTR2CGPR84MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107501099-B | Modulators of ATP-binding cassette transporters | 沃泰克斯药物股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| EP-1773816-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006091870-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1692136-A2 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006002421-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005056554-A2 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1532153-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | AKARNA THERAPEUTICS, LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003099821-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CSNK2A1 4180/4885HTR2A 3159/4885HTR2C 4052/4885 |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | HTR5A, MTNR1A, PTGDR | CSNK2A1 967/4885HTR2A 10/4885HTR2C 6/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | CSNK2A1 218/4885HTR2A 1943/4885HTR2C 2199/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | CSNK2A1 4180/4885HTR2A 3159/4885HTR2C 4052/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | CSNK2A1 3712/4885HTR2A 3661/4885HTR2C 4345/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | CSNK2A1 227/4885HTR2A 1657/4885HTR2C 2007/4885 |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | GPR119, IRS1, INSR | CSNK2A1 2973/4885HTR2A 309/4885HTR2C 974/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | CSNK2A1 227/4885HTR2A 1657/4885HTR2C 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.